Cystic Fibrosis

  • Dubhfeasa Maire Slattery
  • Veronica Donoghue


Cystic fibrosis is a complex, multiorgan disorder primarily affecting the respiratory and gastrointestinal tract, pancreas and hepatobiliary system. It has an incidence of approximately 1 in 2,500 births. Presentation of cystic fibrosis varies according to age. The commonest presentation of cystic fibrosis is with recurrent respiratory tract infections ± associated failure to thrive, secondary to pancreatic exocrine insufficiency. Eighty-five percent of people with cystic fibrosis are pancreatic insufficient and without treatment they malabsorb fat and present with failure to gain weight, abdominal cramps, abdominal distension and steatorrhea. Ten to fifteen percent of cystic fibrosis presentations are in the neonatal period with meconium ileus which may lead to bowel obstruction, perforation and peritonitis. Older children may present with finger clubbing and respiratory symptoms, nasal polyps or acute pancreatitis.


Cystic Fibrosis Patient Nasal Polyp Nasal Polyposis High Resolution Compute Tomography Bronchial Wall 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Matsui H, Grub BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95:1005–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Cystic fibrosis genetic analysis consortium. Cystic fibrosis mutation data base. (1989). Updated 2 March 2007. Accessed 29 May 2011
  6. 6.
    Cleveland RH, Zurakowski D, Slattery D, Colin AA. Cystic fibrosis genotype and assessing rates of decline in pulmonary status. Radiology. 2009;253:813–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Le Grys VA. Sweat testing for the diagnosis of cystic fibrosis: practical considerations. J Pediatr. 1996;129:892–7.CrossRefGoogle Scholar
  8. 8.
    Monaghan KG, Feldman GL. The risk of cystic fibrosis with prenatally detected echogenic bowel in an ethnically and socially diverse North American population. Prenat Diagn. 1999;19:604–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Cleveland RH, Neish AS, Zurakowski D, Nichols DP, Wohl ME, Colin AA. Cystic fibrosis: a system for assessing and predicting progression. Am J Roentgenol. 1998;170:1067–72.Google Scholar
  10. 10.
    Cleveland RH, Neish AS, Zurakowski D, Nichols DP, Wohl ME, Colin AA. Cystic fibrosis: predictors of accelerated decline and distribution of disease in 230 patients. Am J Roentgenol. 1998;171:1311–5.Google Scholar
  11. 11.
    Slattery DM, Zurakowski D, Colin AA, Cleveland RH. CF: an X-ray database to assess effect of aerosolized tobramycin. Pediatr Pulmonol. 2004;38(1):23–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Bhalla M et al. Cystic fibrosis: scoring system with thin section. CT Radiology. 1991;179:783–8.Google Scholar
  13. 13.
    Canadian Cystic Fibrosis Foundation. Report of the Canadian Patient Data registry 2002. Toronto, Ontario, 2002Google Scholar
  14. 14.
    Cystic fibrosis foundation. Patient Registry 2004 Annual Report. Bethesda, Maryland, 2005Google Scholar
  15. 15.
    Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J. 2007;29:522–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang EE, Prober CG, Manson B, et al. Association of respiratory viral infection with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Abman SH, Ogle JW, Butler-Somin N, et al. Role of ­respiratory syncytial virus in early hospitalization for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Smyth AR, Smyth RL, Tong CY, et al. Effect of respiratory virus infections, including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. 1995;73:117–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Wat D, Doull I. Respiratory virus infections in cystic fibrosis. Pediatr Respir Rev. 2003;4:172–7.CrossRefGoogle Scholar
  20. 20.
    Ramsey BW, Gore EJ, Smith AL, et al. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child. 1989;143:662–8.PubMedGoogle Scholar
  21. 21.
    Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory infection on lung function in infants with cystic fibrosis. Pediatrics. 1999;103:619–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Peterson NT, Hoiby N, Mordhorst CH, et al. Respiratory infections in cystic fibrosis patients caused by virus, Chlamydia and mycoplasma: possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981;70:623–8.CrossRefGoogle Scholar
  23. 23.
    Collinson J, Nicholson KG, Cancio JB, et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax. 1996;51:1115–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Abman SH, Ogle JW, Harbeck RJ, et al. Early bacteriologic, immunologic and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr. 1991;119:211–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Pribble CG, Black PG, Bosso A, et al. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. Pediatrics. 1990;117:200–4.CrossRefGoogle Scholar
  26. 26.
    Conway SP, Simmonds EJ, Littlewood JM. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax. 1991;47:112–4.CrossRefGoogle Scholar
  27. 27.
    Bhalla P, Tan A, Smyth R. Vaccines for preventing influenza in people with cystic fibrosis. The cochrane database of systemic reviews 2000. Issue 1. Art. no. CD001753Google Scholar
  28. 28.
    Armstrong DS, Grimwood K, Carlin JB, et al. Lower ­airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1197–204.PubMedGoogle Scholar
  29. 29.
    Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356–66.PubMedCrossRefGoogle Scholar
  30. 30.
    Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995;20:63–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Chimiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of C.F. lung disease. Clin Rev Allergy Immunol. 2002;23:5–27.CrossRefGoogle Scholar
  32. 32.
    Bradley J, McAlister O, Elborn JS. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Resp J. 2001;17:712–5.CrossRefGoogle Scholar
  33. 33.
    Lyczak JB, Cannon CL, Peir GM. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15:194–222.PubMedCrossRefGoogle Scholar
  34. 34.
    Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 1995;48:1041–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Parad RJ, Gerard CJ, Zurakowski D, et al. Pulmonary outcome in cystic fibrosis in influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infec Immun. 1999;67:4744–50.Google Scholar
  36. 36.
    Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros. 2004;3:223–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Watt AP, Courtney J, Moore J, et al. Neutrophil cell death, activation and bacterial infection in Cystic Fibrosis. Thorax. 2005;60:659–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Cheng K, Smyth RL, Govan JR, et al. Spread of a beta-lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348:639–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Jones AM, Webb AK, Govan JR, et al. Pseudomonas aeruginosa cross-infection in cystic fibrosis. Lancet. 2002;359:527–8.PubMedCrossRefGoogle Scholar
  40. 40.
    O’Carroll MR, Syrmis MW, Wainwright CE, et al. Clonal strains of pseudomonas aeruginosa in pediatric and adult cystic fibrosis units. Eur Resp J. 2004;24:101–6.CrossRefGoogle Scholar
  41. 41.
    Jones AM, Dodd ME, Govan JR, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med. 2005;171:257–60.PubMedCrossRefGoogle Scholar
  42. 42.
    Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol. 2000;29:177–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatrics. 2002;140:299–305.CrossRefGoogle Scholar
  44. 44.
    Gibson RL, Burns J, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med. 2003;168:918–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Elborn JS. Treatment of Staphylococcus aureus in cystic fibrosis. Thorax. 1999;54:377–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Conway S, Denton M. Staphylococcus aureus and MRSA. Prog Respir Res. 2006;34:153–9.Google Scholar
  47. 47.
    Mc Manus TE, Moore JE, Crowe M, et al. A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection. J Infect. 2003;46:56–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Koch C, Hoiby N. Diagnosis and treatment of cystic fibrosis. Respiration. 2000;67:239–47.PubMedCrossRefGoogle Scholar
  49. 49.
    Beardsmore CS, Thompson JR, Williams A, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child. 1994;71:133–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Marshall BC. Pulmonary exacerbations in cystic fibrosis: it’s time to be explicit! Am J Respir Crit Care Med. 2004;169:781–2.PubMedCrossRefGoogle Scholar
  51. 51.
    Weaver LT, Green MR, Nicholson K, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child. 1994;70:84–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Miall LS, McKinley NT, Brownlee KG, Conway SP. Methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child. 2001;84:160–2.PubMedCrossRefGoogle Scholar
  53. 53.
    Thomas SR, Gyi KM, Gaya H, Hodson ME. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect. 1998;40:203–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Palvecino E. Community acquired MRSA infections. Clin Lab Med. 2004;24:403–18.CrossRefGoogle Scholar
  55. 55.
    Garske LA, Kid TJ, Gan R, et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect. 2004;56:208–14.PubMedCrossRefGoogle Scholar
  56. 56.
    Henry DA, Campbell MR, LiPuma JJ, Speert DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol. 1997;35:614–9.PubMedGoogle Scholar
  57. 57.
    McMenamin JD, Zaccone TM, Coenye T, et al. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centres: an analysis of 1051 recent sputum isolates. Chest. 2000;117:1661–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Govan JR, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet. 1993;342:15–9.PubMedCrossRefGoogle Scholar
  59. 59.
    McCloskey M, McCaughern J, Redmond AOB, Elborn JS. Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis. Irish J Med Sci. 2001;170:28–31.PubMedCrossRefGoogle Scholar
  60. 60.
    Courtney JM, Dunbar KEA, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cys Fibros. 2004;3:93–8.CrossRefGoogle Scholar
  61. 61.
    Frangolias DD, Mahenthiralingam E, Rae S, et al. Burkholderia cepacia in cystic fibrosis: variable disease course. Am J Respir Crit Care Med. 1999;160:1572–7.PubMedGoogle Scholar
  62. 62.
    DeSoyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet. 2001;358:1780–1.CrossRefGoogle Scholar
  63. 63.
    Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am J Respir Crit Care Med. 2001;164:2102–6.PubMedGoogle Scholar
  64. 64.
    Jones AM, Dodd ME, Govan JRW, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax. 2004;59:948–51.PubMedCrossRefGoogle Scholar
  65. 65.
    Olivier KN, Weber DJ, Wallace RJ, et al. Non-tuberculous mycobacteria :I: Mulitcenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828–34.PubMedCrossRefGoogle Scholar
  66. 66.
    American Thoracic Society. Diagnosis and treatment of disease caused by non- tuberculous mycobacteria. [This official statement of the American Thoracic Society was approved by the board of directors, March1997.]. Am J Respir Crit Care Med. 1997;156:S1–25.Google Scholar
  67. 67.
    Martinez S, Page McAdams H, Batchu CS. The many faces of pulmonary nontuberculous mycobacterial infection. Am J Roentgenol. 2007;199:177–86.CrossRefGoogle Scholar
  68. 68.
    Olivier KN, Weber DJ, Lee JH, et al. Non-tuberculous mycobacteria.II: nested– cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003;167:835–40.PubMedCrossRefGoogle Scholar
  69. 69.
    Cullen A, Cannon CL, Mark EJ, Colin AA. Mycobacteria abscessus infection in cystic fibrosis. Colonization or infection? Am J Resp Crit Care Med. 2000;161((2 pt 1)):641–5.PubMedGoogle Scholar
  70. 70.
    Schidlow DV, Taussig LM, Knowles MR. Cystic fibrosis foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol. 1993;15:187–98.PubMedCrossRefGoogle Scholar
  71. 71.
    Fairfax AJ, Ball J, Batten JC, et al. A pathological study following bronchial artery embolisation for haemoptysis in cystic fibrosis. Br J Dis Chest. 1980;74:345–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Sweezey NB, Fellows KE, Boat TF, et al. Treatment and prognosis of massive haemoptysis in cystic fibrosis. Am Rev Respir Dis. 1978;117:825–8.Google Scholar
  73. 73.
    Stern RC, Wood RE, Boat TF, et al. Treatment and prognosis of massive severe hemoptysis in cystic fibrosis. Am Rev Respir Dis. 1978;117:825–8.PubMedGoogle Scholar
  74. 74.
    Cohen AM. Haemoptysis: role of angiography and embolisation. Pediatr Pulmonol. 1992;8(Suppl):85–6.Google Scholar
  75. 75.
    Barben J, Robertson D, Olinsky A, et al. Bronchial artery embolisation in young patients with cystic fibrosis. Radiology. 2002;224:124–30.PubMedCrossRefGoogle Scholar
  76. 76.
    Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest. 2005;128:729–38.PubMedCrossRefGoogle Scholar
  77. 77.
    Penketh AR, Knight RK, Hodson ME, et al. Management of pneumothorax in adults with cystic fibrosis. Thorax. 1982;37:850–3. otic-associated.PubMedCrossRefGoogle Scholar
  78. 78.
    Northfield TC. Oxygen therapy for spontaneous pneumothorax. Br Med J. 1971;4(5779):86–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Spector ML, Stern RC. Pneumothorax in cystic fibrosis: a 26-year experience. Ann Thorac Surg. 1989;47:204–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Flume PA, Strnage C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest. 2005;128:720–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Mastella G, Rainisio M, Harms HK, et al. For the epidemiologic registry of cystic fibrosis. allergic broncho-pulmonary aspergillosis in cystic fibrosis: a european epidemiological study. Eur Resp J. 2000;16:464–71.CrossRefGoogle Scholar
  82. 82.
    Geller DE, Kaplowitz H, Light MJ, Colin AA. For the scientific advisory group, investigators and coordinators of the epidemiologic study of cystic fibrosis. allergic broncho-pulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution and patient characteristics. Chest. 1999;116:639–46.PubMedCrossRefGoogle Scholar
  83. 83.
    Stevens DA, Moss RB, Kurup VP, et al. Allergic broncho-pulmonary aspergillosis in cystic fibrosis: state of the art: cystic Fibrosis Consensus Conference. Clin Infect Dis. 2003;37 Suppl 3:S225–64.PubMedCrossRefGoogle Scholar
  84. 84.
  85. 85.
    Wark P. Pathogenesis of allergic broncho-pulmonary aspergillosis and an evidence- based review of azoles in treatment. Respir Med. 2004;98:915–23.PubMedCrossRefGoogle Scholar
  86. 86.
    Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic broncho-pulmonary aspergillosis. N Eng J Med. 2000;342:756–62.CrossRefGoogle Scholar
  87. 87.
    Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111:952–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Slieker MG, Schilder AG, Uiterwaal CS, Van der Ent CK. Children with cystic fibrosis: who should visit the otorhinolaryngologist? Arch Otolaryngol Head Neck Surg. 2002;128:1245–8.PubMedGoogle Scholar
  89. 89.
    Brihaye P, Jorissen M, Clement PA. Chronic rhinosinusitis in cystic fibrosis (mucoviscidosis). Acta Otorhinolaryngol Belg. 1997;51:323–37.PubMedGoogle Scholar
  90. 90.
    Hadfield PJ, Rowe-Jones JM, Mackay IS. The prevalence of nasal polyps in adults with cystic fibrosis. Clin Otolaryngol Allied Sci. 2000;25:19–22.PubMedCrossRefGoogle Scholar
  91. 91.
    Coste A, Gilain L, Roger G, et al. Endoscopic and CT-scan evaluation of rhinosinusitis in cystic fibrosis. Rhinology. 1995;33:152–6.PubMedGoogle Scholar
  92. 92.
    GentileVG IG. Paranasal sinus disease in patients with cystic fibrosis. Otolaryngol Clin N Am. 1996;29:193–205.Google Scholar
  93. 93.
    Brihaye P, Clement PA, Dab I, Desprechin B. Pathological changes of the lateral nasal wall in patients with cystic fibrosis (mucoviscidosis). Int J Pediatr Otorhinolaryngol. 1994;28(2–3):141–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Henriksson G, Westrin KM, Karpati F, et al. Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage fluid analysis. Chest. 2002;121:40–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Cimmino M, Cavaliere M, Nardone M, et al. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis. Clin Ololaryngol Allied Sci. 2003;28:125–32.CrossRefGoogle Scholar
  96. 96.
    Hadfield PJ, Rowe-Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology. 2000;38(2):63–5.PubMedGoogle Scholar
  97. 97.
    Rowe-Jones JM, Mackay IS. Endoscopic sinus surgery in the treatment of cystic fibrosis with nasal polyposis. Laryngoscope. 1996;106(12 Pt 1):1540–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Davidson TM, Murphy C, Mitchell M, et al. Management of chronic sinusitis in cystic fibrosis. Laryngoscope. 1995;105(4 Pt 1):354–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics. 1986;78:473–9.PubMedGoogle Scholar
  100. 100.
    O’Halloran SM, Gilbert J, Mckendrick OM, et al. Gastrografin in acute meconium ileus equivalent. Arch Dis Child. 1986;61:1128–30.PubMedCrossRefGoogle Scholar
  101. 101.
    Vic P, Tassin E, Turck D, et al. Frequency of gastro-oesophageal reflux in infants and in young children with cystic fibrosis. Arch Pediatr. 1995;2:742–6 [in French].PubMedCrossRefGoogle Scholar
  102. 102.
    Malfoot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. Arch Dis Child. 1991;66:1339–45.CrossRefGoogle Scholar
  103. 103.
    Brodzicki J, Trawinska-Bartnicka M, Korzon M. Frequency, consequences and pharmacological treatment of gastro-oesophageal reflux in children with cystic fibrosis. Med Sci Monit. 2002;8:CR529–37.PubMedGoogle Scholar
  104. 104.
    Gustafsson PM, Fransson SG, Kjellman NI, et al. Gastro-oesophageal reflux and severity of pulmonary disease in cystic fibrosis. Scand J Gastroenterol. 1991;26:449–56.PubMedCrossRefGoogle Scholar
  105. 105.
    Fitzsimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997;336:1283–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Breckenridghe A, Raine J. Concern about records of fibrosing colonopathy study. Lancet. 2001;357:1527.CrossRefGoogle Scholar
  107. 107.
    Baxter PS, Goldhill J, Hardcastle J. Accounting for cystic fibrosis. Nature. 1988;335:211.PubMedCrossRefGoogle Scholar
  108. 108.
    Corbett K, Kelleher S, Rowland M, et al. Cystic fibrosis associated liver disease: a population–based study. J Pediatr. 2004;145:327–32.PubMedCrossRefGoogle Scholar
  109. 109.
    Lamireau T, Monnereau S, Martin S, et al. Epidemiology of liver disease in cystic fibrosis: a longtitudinal study. J Hepatol. 2004;41:920–5.PubMedCrossRefGoogle Scholar
  110. 110.
    McHugo JM, McKeown C, Brown MT, et al. Ultrasound findings in children with cystic fibrosis. Br J Radiol. 1987;60:137–41.PubMedCrossRefGoogle Scholar
  111. 111.
    King LJ, Scurr ED, Murugan N, et al. Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographics. 2000;20:767–77.PubMedGoogle Scholar
  112. 112.
    Angelico M, Gandin C, Canuzzi P, et al. Gallstones in cystic fibrosis: a critical appraisal. Hepatology. 1991;14:768–75.PubMedCrossRefGoogle Scholar
  113. 113.
    Yang Y, Raper SE, Cohn JA, et al. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA. 1993;90:4601–5.PubMedCrossRefGoogle Scholar
  114. 114.
    De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax. 2006;61:627–35.PubMedCrossRefGoogle Scholar
  115. 115.
    Durno C, Corey M, Zielenski J, et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology. 2002;123:1857–64.PubMedCrossRefGoogle Scholar
  116. 116.
    Bourke S, Rooney M, Fitzgerald M, et al. Episodic ­arthropathy in adult cystic fibrosis. Quart J Med. 1987;64:651–9.PubMedGoogle Scholar
  117. 117.
    Rush PJ, Shore A, Coblentz C, et al. The musculoskeletal manifestations of cystic fibrosis. Semin Arthritis Rheum. 1986;15:213–25.PubMedCrossRefGoogle Scholar
  118. 118.
    Braude S, Kennedy H, Hodson M, et al. Hypertrophic osteoarthropathy in cystic fibrosis. Br Med J. 1984;288:822–3.CrossRefGoogle Scholar
  119. 119.
    Tizzano EF, Silver MM, Chitayat D, et al. Differential cellular expression of cystic fibrosis transmembrane regulator in human reproductive tissues: clues for the infertility in patients with cystic fibrosis. Am J Pathol. 1994;144:906–14.PubMedGoogle Scholar
  120. 120.
    Phillipson G. Cystic fibrosis and reproduction. Reprod Fertil Dev. 1998;10:113–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Respiratory MedicineChildren’s University HospitalDublin 1Ireland
  2. 2.Radiology DepartmentChildren’s University HospitalDublinIreland

Personalised recommendations